Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 6/1/2018 |
| Start Date: | August 2004 |
| End Date: | August 2006 |
A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for
adults with obsessive-compulsive disorder and who are currently on serotonin reuptake
inhibitor medications (ages 18-65).
adults with obsessive-compulsive disorder and who are currently on serotonin reuptake
inhibitor medications (ages 18-65).
The Compulsive, Impulsive and Anxiety Disorders Program at the Mount Sinai School of Medicine
is conducting a study of Topiramate (Topamax) added to an SSRI for the management of
treatment-resistant Obsessive-Compulsive Disorder. The purpose of the study is to evaluate
the safety and efficacy of Topiramate versus placebo added to a selective serotonin reuptake
inhibitor (SRI) in patients with treatment resistant OCD. The program is 12 weeks in duration
and involves regular visits with a psychiatrist as well as complete psychiatric and medical
evaluations. Treatment and medication for the study will be provided free of
charge.Participants must be between the ages of 18 and 65 and have an onset of OCD at least 1
year prior to screening. In addition, participants must be taking a clinically effective dose
of an SSRI for at least 3 months and must maintain their current dose throughout the study.
Participants must not have a primary OCD symptom of hoarding.
is conducting a study of Topiramate (Topamax) added to an SSRI for the management of
treatment-resistant Obsessive-Compulsive Disorder. The purpose of the study is to evaluate
the safety and efficacy of Topiramate versus placebo added to a selective serotonin reuptake
inhibitor (SRI) in patients with treatment resistant OCD. The program is 12 weeks in duration
and involves regular visits with a psychiatrist as well as complete psychiatric and medical
evaluations. Treatment and medication for the study will be provided free of
charge.Participants must be between the ages of 18 and 65 and have an onset of OCD at least 1
year prior to screening. In addition, participants must be taking a clinically effective dose
of an SSRI for at least 3 months and must maintain their current dose throughout the study.
Participants must not have a primary OCD symptom of hoarding.
Inclusion Criteria:
Males and Females 18-65 years of age diagnosed with OCD and currently taking SSRI
medication(s)
Exclusion Criteria:
major medical disorders
We found this trial at
1
site
Click here to add this to my saved trials
